Jan-14 -

Leukemia Group

EORTC 06991 – The value of high dose versus standard dose Ara-c during induction and IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 yrs) with acute myelogenous leukemia.

A randomized phase III trial of the EORTC and GIMEMA Leukemia Cooperative Groups (AML-12).

EORTC found higher doses of chemotherapy drug cytarabine during first phase treatment, provided higher response and survival rates than the standard dose, in acute myelogenous leukemia (AML) patients, especially if younger than 46 years old.


Go to Top